Zurück zur Übersicht
| International journal of chronic obstructive pulmonary disease. 2017 Dec 21. doi: 10.2147/COPD.S145573. pii: copd-13-045. pmc: PMC5743110 |
| Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. |
| Ariel A1, Altraja A2, Belevskiy A3, Boros PW4, Danila E5, Fležar M6, Koblizek V7, Fridlender ZG8, Kostov K9, Krams A10, Milenkovic B11, Somfay A12, Tkacova R13, Tudoric N14, Ulmeanu R15, Valipour A16 |
 Author information
|
|
Abstract COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups. |
|
KEYWORDS: LABA, LAMA, anticholinergic, dual bronchodilation, inhaled corticosteroid, tiotropium |
|
Publikations ID: 29317810 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
